RARE News
Archived Headlines
- Ultragenyx increases proposed IPO price range to $19 to $20; deal size is now $94 million 01/29/14
- 6 US IPOs planned for the week of Jan 27 01/27/14
- US IPO Recap: Group of energy-related IPOs comes up dry 01/21/14
- Rare disease biotech Ultragenyx sets terms for $75 million IPO 01/17/14
- Rare disease biotech Ultragenyx files for a $86 million IPO 11/08/13
Renaissance IPO Index - Notice of September 2015 Quarterly Changes
The Renaissance IPO Index (Ticker: IPOUSA), the underlying index for the Renaissance IPO ETF (Ticker: IPO), will implement the following constituent changes at the market’s...read more
US IPO Recap: Varonis provides data security for enterprises and financial security for investors
The year's first software IPO, Varonis Systems (VRNS), gained 100% on the first day of trading after pricing 22% above the midpoint of the original range. It marked the third IPO this year to have a 100% or greater first-day return after Dicerna (DRNA) and...read more
US IPO Recap: Ultragenyx doubles and Dicerna triples in home-run week for biotech IPOs
Dicerna Pharmaceuticals (DRNA) gained 207% and Ultragenyx (RARE) followed with a 101% first-day jump the next day as the biotech boom reached a new gear last week. Dicerna’s first-day return was the best since Baidu’s IPO in 2005 (+354%), and...read more
Ultragenyx prices upsized IPO at $21, above the range
Ultragenyx Pharmaceutical, a clinical-stage biotech developing treatments for rare metabolic genetic diseases, raised $121 million by offering 5.8 million shares at $21, above the range of $19 to $20. Ultragenyx Pharmaceutical plans to list on the NASDAQ under...read more